Medication choices in juvenile rheumatoid arthritis.
This survey was performed to review medication usage by pediatric rheumatologists in the care of patients with juvenile rheumatoid arthritis (JRA). Prospective data from 50 patients per physician with JRA were recorded by six pediatric rheumatologists in the Fall of 1993. Naproxen was used most frequently-in 48% of all patients. Next in order of frequency were methotrexate (39%), prednisone (15%), tolmetin (12%), indomethacin (11%) and folic acid (10%). Salicylates (acetylsalicylic acid, trisalicylate and salsalate) were used in 7%, and myochrysine was used in 2% of patients. Overall, nonsteroidal anti-inflammatory drugs were used in 93% of all patients, slower-acting antirheumatic drugs (SAARDs) were used in 54% and prednisone in 15%.Medication usage varied by disease type in predictable ways but also varied by physician in ways that could not be accounted for by population differences. Methotrexate was the most-often used of all SAARDs and supplanted myochrysine in JRA. Naproxen was the most often used NSAID in the treatment of JRA and had largely supplanted salicylates. With the arrival of practice guidelines, reasons for and impact of these changes (as well as the interesting variations between physicians) will need to be examined.
Mier
R
R
Shriners Hospital, Lexington, Kentucky (R.M., S.C.); University of Kentucky (R.M.); Children's Hospital Medical Center, Cincinnati, Ohio (D.L., M.P.); James Whitcomb Riley Hospital, Indianapolis, Indiana (S.B.); Children's Hospital, Columbus, Ohio (R.R.); and University of Louisville, Louisville, Kentucky (K.S.).
Lovell
D
D
Bowyer
S
S
Passo
M
M
Rennebohm
R
R
Schikler
K
K
Coates
S
S